Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study
Autor(a) principal: | |
---|---|
Data de Publicação: | 2014 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | http://dx.doi.org/10.1016/j.bjid.2013.05.007 http://repositorio.unifesp.br/handle/11600/8202 |
Resumo: | Background: Tolerance and response to antiviral HCV treatment is poor in advanced fibrosis. The aim of this study was to assess SVR rate and its predictive factors in HCV advanced fibrosis patients treated in real life with full dose PEG-IFN plus RBV and to evaluate the adverse events related to treatment. Methods: A multicentric, retrospective study was conducted at six university hospitals. METAVIR F3 and F4 HCV monoinfected patients who were treated with PEG-IFN and RBV had their data analyzed. A stepwise logistic regression analysis was performed to identify the variables independently related to SVR. Adverse events were recorded during treatment. Results: 308 patients were included, 75% genotype 1 and 23% genotype 3. METAVIR F3 was present in 39% and F4 in 61% of patients. The median Child Pugh score for F4 patients was 5 (5–9). The global SVR rate was 34%, 11% were relapsers and 55% were nonresponders. SVR rates were similar between patients treated with PEG-IFN alfa 2a or alfa 2b (p = 0.24). SVR rates according to Child–Pugh score were 26% (Child A) and 18% (Child B). The independent factors related to SVR in F4 patients were genotype 3, RVR and fewer Child Pugh score points. Treatment interruption occurred in 31% patients and death occurred in 1.9%, all with liver cirrhosis. Conclusion: Treatment of HCV in patients with advanced fibrosis should not be postponed. However, a very careful evaluation of cirrhotic patients must be performed before treatment is indicated and careful monitoring is required during treatment. |
id |
UFSP_9b829fd942e7d41f3a9237e7a6a2a29b |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br/:11600/8202 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life studyHepatitis CAdvanced fibrosisPeginterferonRibavirinBackground: Tolerance and response to antiviral HCV treatment is poor in advanced fibrosis. The aim of this study was to assess SVR rate and its predictive factors in HCV advanced fibrosis patients treated in real life with full dose PEG-IFN plus RBV and to evaluate the adverse events related to treatment. Methods: A multicentric, retrospective study was conducted at six university hospitals. METAVIR F3 and F4 HCV monoinfected patients who were treated with PEG-IFN and RBV had their data analyzed. A stepwise logistic regression analysis was performed to identify the variables independently related to SVR. Adverse events were recorded during treatment. Results: 308 patients were included, 75% genotype 1 and 23% genotype 3. METAVIR F3 was present in 39% and F4 in 61% of patients. The median Child Pugh score for F4 patients was 5 (5–9). The global SVR rate was 34%, 11% were relapsers and 55% were nonresponders. SVR rates were similar between patients treated with PEG-IFN alfa 2a or alfa 2b (p = 0.24). SVR rates according to Child–Pugh score were 26% (Child A) and 18% (Child B). The independent factors related to SVR in F4 patients were genotype 3, RVR and fewer Child Pugh score points. Treatment interruption occurred in 31% patients and death occurred in 1.9%, all with liver cirrhosis. Conclusion: Treatment of HCV in patients with advanced fibrosis should not be postponed. However, a very careful evaluation of cirrhotic patients must be performed before treatment is indicated and careful monitoring is required during treatment.Universidade Estadual Paulista (UNESP) Botucatu School of MedicineUniversidade Federal do Rio de JaneiroUniversidade Estadual de CampinasUniversidade Federal de São Paulo (UNIFESP)Pontificia Universidade Catolica de São PauloUNIFESP, EPM, São PauloSciELOBrazilian Society of Infectious DiseasesUniversidade Estadual Paulista (UNESP)Universidade Federal do Rio de JaneiroUniversidade Estadual de Campinas (UNICAMP)Universidade Federal de São Paulo (UNIFESP)Pontificia Universidade Catolica de São PauloSilva, Giovanni FariaVillela-nogueira, Cristiane A.Mello, Carlos Eduardo BrandaoSoares, Elza CotrimCoelho, Henrique Sergio M.Ferreira, Paulo Roberto Abrão [UNIFESP]Ruiz, Fernando Jose Goes2015-06-14T13:46:54Z2015-06-14T13:46:54Z2014-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion48-52application/pdfhttp://dx.doi.org/10.1016/j.bjid.2013.05.007Brazilian Journal of Infectious Diseases. Brazilian Society of Infectious Diseases, v. 18, n. 1, p. 48-52, 2014.10.1016/j.bjid.2013.05.007S1413-86702014000100048.pdf1413-8670S1413-86702014000100048http://repositorio.unifesp.br/handle/11600/8202WOS:000332911100008engBrazilian Journal of Infectious Diseasesinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-07-28T13:18:17Zoai:repositorio.unifesp.br/:11600/8202Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-07-28T13:18:17Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.none.fl_str_mv |
Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study |
title |
Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study |
spellingShingle |
Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study Silva, Giovanni Faria Hepatitis C Advanced fibrosis Peginterferon Ribavirin |
title_short |
Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study |
title_full |
Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study |
title_fullStr |
Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study |
title_full_unstemmed |
Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study |
title_sort |
Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study |
author |
Silva, Giovanni Faria |
author_facet |
Silva, Giovanni Faria Villela-nogueira, Cristiane A. Mello, Carlos Eduardo Brandao Soares, Elza Cotrim Coelho, Henrique Sergio M. Ferreira, Paulo Roberto Abrão [UNIFESP] Ruiz, Fernando Jose Goes |
author_role |
author |
author2 |
Villela-nogueira, Cristiane A. Mello, Carlos Eduardo Brandao Soares, Elza Cotrim Coelho, Henrique Sergio M. Ferreira, Paulo Roberto Abrão [UNIFESP] Ruiz, Fernando Jose Goes |
author2_role |
author author author author author author |
dc.contributor.none.fl_str_mv |
Universidade Estadual Paulista (UNESP) Universidade Federal do Rio de Janeiro Universidade Estadual de Campinas (UNICAMP) Universidade Federal de São Paulo (UNIFESP) Pontificia Universidade Catolica de São Paulo |
dc.contributor.author.fl_str_mv |
Silva, Giovanni Faria Villela-nogueira, Cristiane A. Mello, Carlos Eduardo Brandao Soares, Elza Cotrim Coelho, Henrique Sergio M. Ferreira, Paulo Roberto Abrão [UNIFESP] Ruiz, Fernando Jose Goes |
dc.subject.por.fl_str_mv |
Hepatitis C Advanced fibrosis Peginterferon Ribavirin |
topic |
Hepatitis C Advanced fibrosis Peginterferon Ribavirin |
description |
Background: Tolerance and response to antiviral HCV treatment is poor in advanced fibrosis. The aim of this study was to assess SVR rate and its predictive factors in HCV advanced fibrosis patients treated in real life with full dose PEG-IFN plus RBV and to evaluate the adverse events related to treatment. Methods: A multicentric, retrospective study was conducted at six university hospitals. METAVIR F3 and F4 HCV monoinfected patients who were treated with PEG-IFN and RBV had their data analyzed. A stepwise logistic regression analysis was performed to identify the variables independently related to SVR. Adverse events were recorded during treatment. Results: 308 patients were included, 75% genotype 1 and 23% genotype 3. METAVIR F3 was present in 39% and F4 in 61% of patients. The median Child Pugh score for F4 patients was 5 (5–9). The global SVR rate was 34%, 11% were relapsers and 55% were nonresponders. SVR rates were similar between patients treated with PEG-IFN alfa 2a or alfa 2b (p = 0.24). SVR rates according to Child–Pugh score were 26% (Child A) and 18% (Child B). The independent factors related to SVR in F4 patients were genotype 3, RVR and fewer Child Pugh score points. Treatment interruption occurred in 31% patients and death occurred in 1.9%, all with liver cirrhosis. Conclusion: Treatment of HCV in patients with advanced fibrosis should not be postponed. However, a very careful evaluation of cirrhotic patients must be performed before treatment is indicated and careful monitoring is required during treatment. |
publishDate |
2014 |
dc.date.none.fl_str_mv |
2014-01-01 2015-06-14T13:46:54Z 2015-06-14T13:46:54Z |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.1016/j.bjid.2013.05.007 Brazilian Journal of Infectious Diseases. Brazilian Society of Infectious Diseases, v. 18, n. 1, p. 48-52, 2014. 10.1016/j.bjid.2013.05.007 S1413-86702014000100048.pdf 1413-8670 S1413-86702014000100048 http://repositorio.unifesp.br/handle/11600/8202 WOS:000332911100008 |
url |
http://dx.doi.org/10.1016/j.bjid.2013.05.007 http://repositorio.unifesp.br/handle/11600/8202 |
identifier_str_mv |
Brazilian Journal of Infectious Diseases. Brazilian Society of Infectious Diseases, v. 18, n. 1, p. 48-52, 2014. 10.1016/j.bjid.2013.05.007 S1413-86702014000100048.pdf 1413-8670 S1413-86702014000100048 WOS:000332911100008 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Brazilian Journal of Infectious Diseases |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
48-52 application/pdf |
dc.publisher.none.fl_str_mv |
Brazilian Society of Infectious Diseases |
publisher.none.fl_str_mv |
Brazilian Society of Infectious Diseases |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
biblioteca.csp@unifesp.br |
_version_ |
1814268311601414144 |